Literature DB >> 23582654

A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia.

Tushar Baheti1, Anuradha Nischal2, Anil Nischal3, Sanjay Khattri4, Amit Arya5, Adarsh Tripathi6, K K Pant7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23582654     DOI： 10.1016/j.schres.2013.03.017

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  6 in total

1.  Targeting the Immune System with Pharmacotherapy in Schizophrenia.

Authors:  Jennifer K Melbourne; Benjamin Feiner; Cherise Rosen; Rajiv P Sharma
Journal:  Curr Treat Options Psychiatry       Date:  2017-04-18

Review 2.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.

Authors:  Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

3.  Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk.

Authors:  Carrie Wright; Vince D Calhoun; Stefan Ehrlich; Lei Wang; Jessica A Turner; Nora I Perrone- Bizzozero
Journal:  Front Genet       Date:  2015-04-20       Impact factor: 4.599

Review 4.  Modulating Neuroinflammation to Treat Neuropsychiatric Disorders.

Authors:  Franziska A Radtke; Gareth Chapman; Jeremy Hall; Yasir A Syed
Journal:  Biomed Res Int       Date:  2017-10-18       Impact factor: 3.411

Review 5.  Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials.

Authors:  Stefano Marini; Domenico De Berardis; Federica Vellante; Rita Santacroce; Laura Orsolini; Alessandro Valchera; Gabriella Girinelli; Alessandro Carano; Michele Fornaro; Francesco Gambi; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Mediators Inflamm       Date:  2016-07-25       Impact factor: 4.711

6.  Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Somaye Arabzadeh; Atefeh Zeinoddini; Seyed-Ali Mostafavi; Mehdi Hamedi; Abolfazl Ehyaii; Ali Ghaleiha; Arefeh Zeinoddini; Shahin Akhondzadeh
Journal:  Iran J Psychiatry       Date:  2018-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.